Head-to-head evidence
teriflunomide HMR1726 vs vidofludimus calcium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: Dihydroorotate dehydrogenase (DHODH) · full Multiple Sclerosis pipeline
teriflunomide HMR1726
Marketed by Sanofi
NCT03122652 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled trial of 125 participants met its primary endpoint: teriflunomide reduced the risk of a first clinical demyelinating event by about 63 to 72% compared with placebo, a statistically significant result.
vidofludimus calcium
Developed by Immunic, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT05201638 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: teriflunomide HMR1726's landscape · vidofludimus calcium's landscape